Free Trial
NASDAQ:NTHI

Neonc Technologies Q1 2025 Earnings Report

Neonc Technologies logo
$4.54 -0.21 (-4.44%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Neonc Technologies EPS Results

Actual EPS
-$2.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Neonc Technologies Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neonc Technologies Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Neonc Technologies' next earnings date is estimated for Friday, August 14, 2026, based on past reporting schedules.

Conference Call Resources

Neonc Technologies Earnings Headlines

From Nokia to NeOnc: The Stocks Dominating Screens as Volume Spikes
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free.tc pixel
The Next Great AI Revolution May Be Drug Delivery
See More Neonc Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neonc Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neonc Technologies and other key companies, straight to your email.

About Neonc Technologies

Neonc Technologies (NASDAQ:NTHI) develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

View Neonc Technologies Profile